Log in

OTCMKTS:BTCY - Biotricity Stock Price, Forecast & News

0.00 (0.00 %)
(As of 12/16/2019 07:33 AM ET)
Today's Range
Now: $0.35
50-Day Range
MA: $0.50
52-Week Range
Now: $0.35
Volume99,899 shs
Average Volume43,961 shs
Market Capitalization$12.55 million
P/E RatioN/A
Dividend YieldN/A
Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, focuses on providing biometric data monitoring solutions in the United States. The company focuses to deliver remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It is developing Bioflux mobile cardiac telemetry solution that provides recurring reimbursements to doctors, hospitals, and independent diagnostic testing facilities; revenue model that fits within the established insurance billing practices; built-in cellular connectivity; and motion tracking to detect exercise, activity, and disorientation. The company is also developing Biolife, a health and lifestyle solution for individuals. It has a collaboration agreement with the University of Calgary to determine the predictive value of electrocardiogram readings in preventative healthcare applications. Biotricity, Inc. is based in Redwood City, California.

Industry, Sector and Symbol

Industry Electric services
Current SymbolOTCMKTS:BTCY



Sales & Book Value

Annual SalesN/A



Market Cap$12.55 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BTCY News and Ratings via Email

Sign-up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter.

Biotricity (OTCMKTS:BTCY) Frequently Asked Questions

What is Biotricity's stock symbol?

Biotricity trades on the OTCMKTS under the ticker symbol "BTCY."

Has Biotricity been receiving favorable news coverage?

Media coverage about BTCY stock has trended somewhat negative this week, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biotricity earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Biotricity.

Who are some of Biotricity's key competitors?

What other stocks do shareholders of Biotricity own?

Who are Biotricity's key executives?

Biotricity's management team includes the folowing people:
  • Mr. Waqaas Al-Siddiq, Founder, Pres, CEO & Chairman (Age 34)
  • Mr. John Ayanoglou, Chief Financial Officer (Age 53)
  • Mr. Casey Shattuck, Global VP of Sales
  • Mr. Amir Ali, Chief Devel. Officer
  • Mr. Spencer LaDow, VP of Engineering

How do I buy shares of Biotricity?

Shares of BTCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biotricity's stock price today?

One share of BTCY stock can currently be purchased for approximately $0.35.

How big of a company is Biotricity?

Biotricity has a market capitalization of $12.55 million. View Additional Information About Biotricity.

MarketBeat Community Rating for Biotricity (OTCMKTS BTCY)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  109
MarketBeat's community ratings are surveys of what our community members think about Biotricity and other stocks. Vote "Outperform" if you believe BTCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel